Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:04
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…
Entries by arcticnovartis
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:03
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04
Read more about Novartis showcases significant immunology advancements in ACR congress with …
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04
Read more about Novartis showcases significant immunology advancements in ACR congress with …
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
arcticnovartis
Wed, 10/22/2025 – 07:19
Read more about Novartis Cosentyx® meets primary and all secondary endpoints in Ph…
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
arcticnovartis
Wed, 10/22/2025 – 07:04
Read more about Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offe…
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
arcticnovartis
Sun, 10/19/2025 – 16:34
Read more about PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
…
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis
Fri, 10/17/2025 – 14:04
Read more about Novartis Kisqali® 5-year NATALEE data demonstrate 2…
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis
Fri, 10/17/2025 – 12:49
Read more about Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly …
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
arcticnovartis
Thu, 10/16/2025 – 07:19
Read more about Novartis Fabhalta® (iptacopan) meets Phase III primary e…